2012

June 12, 2012
BTG plc: Applications submitted to FDA and EMA for approval of Lemtrada™ (alemtuzumab) for Multiple Sclerosis

London, UK, 12 June 2012 BTG plc (LSE: BTG), the specialist healthcare company, notes today’s announcement by Sanofi and its subsidiary Genzyme, relating to the submission of a supplemental...

June 04, 2012
BTG announces data presentation on Voraxaze® (glucarpidase) at the American Society of Clinical Oncology Annual Meeting

West Conshohocken, PA, 04 June 2012 BTG International Inc., the specialist healthcare company, today announces the presentation of data on Voraxaze®(glucarpidase) at the American Society of...

May 25, 2012
BTG to present at the Jefferies Global Healthcare Conference

London, UK, 25 May 2012 BTG plc (LSE: BGC), the specialist healthcare company, today announces that Louise Makin, CEO, will be presenting at the Jefferies Global Healthcare Conference in New York,...

May 21, 2012
BTG plc: Final Results

London, UK, 21 May 2012 BTG plc (LSE: BGC), the specialist healthcare company, today announces its final results for the year ended 31 March 2012. Click here to download the PDF

April 30, 2012
Voraxaze® (glucarpidase) Launched in the US

West Conshohocken, PA, 30 April 2012 BTG International Inc., the specialist healthcare company today announces the launch of Voraxaze® (glucarpidase) in the US. Voraxaze® is indicated for the...

Show 5102550100 per page
Top